Article Content

Clinical Trials in the National Cancer Institute's Database

BLADDER CANCER

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 870 locations

 

Primary IDA031501

 

Secondary IDsNCI-2017-01425

 

ClinicalTrials.gov IDNCT03244384

 

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-Cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 525 locations

 

Primary ID A031702

 

Secondary IDs NCI-2019-01266

 

ClinicalTrials.gov ID NCT03866382

 

Testing the Addition of An Anti-Cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 350 locations

 

Primary ID A031803

 

Secondary IDs NCI-2019-07573

 

ClinicalTrials.gov ID NCT04164082

 

Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Invasive Bladder Urothelial Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 351 locations

 

Primary ID A031701

 

Secondary IDs NCI-2018-01531

 

ClinicalTrials.gov ID NCT03609216

 

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 196 locations

 

Primary ID S1806

 

Secondary IDs NCI-2018-03264

 

ClinicalTrials.gov ID NCT03775265

 

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 27 locations

 

Primary ID SGN22E-002

 

Secondary IDs NCI-2017-01927, MK-3475-869

 

ClinicalTrials.gov ID NCT03288545

 

Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 18 locations

 

Primary ID 10183

 

Secondary IDs NCI-2019-01035, ETCTN 10183

 

ClinicalTrials.gov ID NCT03854474

 

Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 19 locations

 

Primary ID QBGJ398-302

 

Secondary IDs NCI-2020-00610, 2019-003248-63

 

ClinicalTrials.gov ID NCT04197986

 

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 14 locations

 

Primary ID CA209-901

 

Secondary IDs NCI-2017-02285, 2016-003881-14

 

ClinicalTrials.gov ID NCT03036098

 

COLORECTAL CANCER

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer, SOLARIS Trial

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 878 locations

 

Primary ID A021703

 

Secondary IDs NCI-2019-01034

 

ClinicalTrials.gov ID NCT04094688

 

Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed By Surgery

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 741 locations

 

Primary ID S1613

 

Secondary IDs NCI-2016-01422

 

ClinicalTrials.gov ID NCT03365882

 

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 901 locations

 

Primary ID A021502

 

Secondary IDs NCI-2016-01417

 

ClinicalTrials.gov ID NCT02912559

 

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 28 locations

 

Primary ID 10181

 

Secondary IDs NCI-2018-01463, NCI-10181

 

ClinicalTrials.gov ID NCT03592641

 

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 28 locations

 

Primary ID XL184-021

 

Secondary IDs NCI-2017-01455

 

ClinicalTrials.gov ID NCT03170960

 

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 22 locations

 

Primary ID SGNTUC-017

 

Secondary IDs NCI-2020-01033, ACCRU-GI-1617, NCI-2017-01107, P30CA015083

 

ClinicalTrials.gov ID NCT03043313

 

Circulating Tumor DNA Testing In Predicting Treatment For Patients With Stage IIA Colon Cancer After Surgery, COBRA Trial

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 684 locations

 

Primary ID NRG-GI005

 

Secondary IDs NCI-2019-01068

 

ClinicalTrials.gov ID NCT04068103

 

Transanal Total Mesorectal Excision With Laparoscopic Assistance in Treating Patients With Rectal Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 12 locations

 

Primary ID 16-2009

 

Secondary IDs NCI-2017-01497

 

ClinicalTrials.gov ID NCT03144765

 

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 12 locations

 

Primary ID CPI-006-001

 

Secondary IDs NCI-2018-02296

 

ClinicalTrials.gov ID NCT03454451

 

A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 15 locations

 

Primary ID 17-262-01

 

Secondary IDs NCI-2018-00619, 2018-004625-84

 

ClinicalTrials.gov ID NCT03435640

 

HEAD & NECK CANCER

Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 460 locations

 

Primary ID EA3132

 

Secondary IDs NCI-2015-01911

 

ClinicalTrials.gov ID NCT02734537

 

De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 272 locations

 

Primary ID NRG-HN005

 

Secondary IDs NCI-2019-03015

 

ClinicalTrials.gov ID NCT03952585

 

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin with Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 233 locations

 

Primary ID NRG-HN007

 

Secondary IDs NCI-2020-04581

 

ClinicalTrials.gov ID NCT04458909

 

Radiation Therapy with Durvalumab or Cetuximab in Treating Patients with Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 225 locations

 

Primary ID NRG-HN004

 

Secondary IDs NCI-2017-01522

 

ClinicalTrials.gov ID NCT03258554

 

Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 166 locations

 

Primary ID NRG-HN001

 

Secondary IDs NCI-2014-00635, NCT02179164, s16-00025, RTOG-1305

 

ClinicalTrials.gov ID NCT02135042

 

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 195 locations

 

Primary ID RTOG-1216

 

Secondary IDs NCI-2013-00500, NCT04411121

 

ClinicalTrials.gov ID NCT01810913

 

LUNG CANCER

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

 

Status: Active

 

Phase III

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 1340 locations

 

Primary ID E4512

 

Secondary IDs NCI-2014-01507, s16-02072

 

Clinicaltrials.gov ID NCT02201992

 

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

 

Status: Active

 

Phase II

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 1185 locations

 

Primary ID EAY131

 

Secondary IDs NCI-2015-00054

 

Clinicaltrials.gov ID NCT02465060

 

Durvalumab and Tremelimumab in Treating Patients with Recurrent Stage IV Lung Cancer (A Lung-MAP Treatment Trial)

 

Status: Active

 

Phase II

 

Age: Not specified

 

Gender: Male or Female

 

Location: 1041 locations

 

Primary ID S1400F

 

Secondary IDs NCI-2016-01597, NCT02154490

 

Clinicaltrials.gov ID NCT03373760

 

Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

 

Status: Active

 

Phase III

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 1291 locations

 

Primary ID A081105

 

Secondary IDs NCI-2014-01508,

 

s16-02079, CALGB A081105

 

Clinicaltrials.gov ID NCT02193282

 

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors

 

Status: Active

 

Phase II

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 839 locations

 

Primary ID S1609

 

Secondary IDs NCI-2016-01041

 

Clinicaltrials.gov ID NCT02834013

 

MELANOMA

A Study to Compare the Administration of Pembrolizumab after Surgery Versus Administration both before and after Surgery for High-Risk Melanoma

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 758 locations

 

Primary ID S1801

 

Secondary IDs NCI-2018-02107

 

ClinicalTrials.gov ID NCT03698019

 

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 722 locations

 

Primary ID EA6134

 

Secondary IDs NCI-2014-01747

 

ClinicalTrials.gov ID NCT02224781

 

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 525 locations

 

Primary ID EA6141

 

Secondary IDs NCI-2014-02674

 

ClinicalTrials.gov ID NCT02339571

 

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients with Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 254 locations

 

Primary ID EA6192

 

Secondary IDs NCI-2020-04463

 

ClinicalTrials.gov ID NCT04462406

 

PROSTATE CANCER

Abiraterone Acetate and Antiandrogen Therapy with or without Cabazitaxel and Prednisone in Treating Patients with Metastatic, Castration-Resistant Prostate Cancer Previously Treated with Docetaxel

 

Status: Active

 

Age: 18 years and over

 

Gender: Male

 

Location: 642 locations

 

Primary ID EA8153

 

Secondary IDs NCI-2017-00389

 

ClinicalTrials.gov ID NCT03419234

 

Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male

 

Location: 249 locations

 

Primary ID S1802

 

Secondary IDs NCI-2018-01738

 

ClinicalTrials.gov ID NCT03678025

 

Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery

 

Status: Active

 

Age: 18 years and over

 

Gender: Male

 

Location: 236 locations

 

Primary ID NRG-GU002

 

Secondary IDs NCI-2016-00963

 

ClinicalTrials.gov ID NCT03070886

 

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male

 

Location: 217 locations

 

Primary ID NRG-GU005

 

Secondary IDs NCI-2017-01398

 

ClinicalTrials.gov ID NCT03367702

 

THYROID CANCER

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

 

Status: Active

 

Age: 12 years and over

 

Gender: Male or Female

 

Location: 27 locations

 

Primary ID LOXO-RET-17001 /J2G-OX-JZJA

 

Secondary IDs NCI-2017-00976, 2017-000800-59, LOXO-RET-17001

 

ClinicalTrials.gov ID NCT03157128

 

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy

 

Status: Active

 

Age: 16 years and over

 

Gender: Male or Female

 

Location: 15 locations

 

Primary ID XL184-311

 

Secondary IDs NCI-2018-03334

 

ClinicalTrials.gov ID NCT03690388

 

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 13 locations

 

Primary ID 10240

 

Secondary IDs NCI-2019-02220

 

ClinicalTrials.gov ID NCT03914300

 

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

 

Status: Active

 

Age: 12 years and over

 

Gender: Male or Female

 

Location: 15 locations

 

Primary ID 17478

 

Secondary IDs NCI-2020-00277, 2019-001978-28, J2G-MC-JZJB

 

ClinicalTrials.gov ID NCT04211337

 

Vemurafenib plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

 

Status: Active

 

Age: 18 years and over

 

Gender: Male or Female

 

Location: 7 locations

 

Primary ID 20-053

 

Secondary IDs NCI-2020-05188

 

ClinicalTrials.gov ID NCT04462471